Denise Strauss, formerly VP of cardiovascular marketing at Boehringer Ingelheim, will oversee the drugmaker's marketing activities.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.
- The 2017 pipeline report: What to know about next year's launches
- Five things for pharma marketers to know: Monday, November 28, 2016
- Lilly's branded app for Trulicity looks to address adherence
- Five things for pharma marketers to know: Tuesday, November 29, 2016
- Lawmakers cut CME exemption from 21st Century Cures Act
- Boehringer Ingelheim launches gamified support program
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Prescription drug spending rises 9% in 2015, to $324 billion
- As users move to mobile, Google says they made 200 million queries for info about cancer drugs
- Five things for pharma marketers to know: Friday, December 2, 2016
- Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.
- Five things for pharma marketers to know: Thursday, December 1, 2016